Latest filingSep 01, 2026Most recent Form 4
ORKA
Oruka Therapeutics, Inc.
NasdaqHealthcarePharmaceutical Preparations
Insider activity for last month from 08/03 to 09/03. Counts use processed Form 4 rows. Purchase and sale metrics use codes P and S; totals remain unknown when any matching value is missing. Rows without a usable transaction date cannot be assigned to a rolling period and are excluded.
Total buying$00 buys
Total selling$812M9 sells
Net open-market-$812M3 insiders
Open-market mix
Buy vs sell distribution by transaction countInsider activity report
Monthly open-market purchase and sale counts Buys Sells
Transaction codes
By Form 4 transaction code in selected period17transactions
- S · Open-market sells · dominant9 · 53%
- M · Option exercise8 · 47%
Activity by reported role
A joint filing can contribute to multiple roles17transactions
- CMO · dominant8 · 47%
- Chief executive officer5 · 29%
- COO4 · 24%
Distinct insiders active
Reporting-owner CIKs by month · peak Sep 2026 (2)Aug 2026Sep 2026
Reported Holdings After
Separated by insider, security, and ownership typeGoncalves JoanaCommon Stock · Direct
32,718Aug 17, 2026
Klein Lawrence OttoCommon Stock · Direct
925,580Sep 01, 2026
Sandler Laura LeeCommon Stock · Direct
236,384Sep 01, 2026
Goncalves JoanaEmployee Stock Option (right to buy) · Direct
197,063Aug 17, 2026
Goncalves JoanaEmployee Warrant (right to buy) · Direct
168,492Aug 17, 2026
Klein Lawrence OttoEmployee Warrant (right to buy) · Direct
1,553,513Sep 01, 2026
Sandler Laura LeeEmployee Warrant (right to buy) · Direct
74,996Sep 01, 2026
These are reported post-transaction holdings, not company-wide ownership percentages. Securities, indirect vehicles, and amendments are kept separate.
Filing activity heatmap
Each cell is one day · intensity = transactions · buys green, sells redAug 03 → Sep 03
LessMore
Top insiders
By absolute net value across the selected period- KO-$6.3M
- GJ-$731.6k
- SL-$420.1k
Recent filing activity
Most recent 12 transactions · color = transaction codeFiling detail checks
Secondary metrics for the selected periodFiling-only signals
Deterministic matches in the selected period
ORKA transaction history
Filters apply within this company and selected period by default| Ticker | Insider | Role | Type | Shares | Value | Code | Signals | 90d return | Filed | Trans date |
|---|---|---|---|---|---|---|---|---|---|---|
| ORKA | Sandler Laura Lee | COO | exercise10b5-1 | 5.00k | $0 | M | 0.0% | 09/01 | 09/01 | |
| ORKA | Sandler Laura Lee | COO | sale10b5-1 | 4.00k | -$36.8M | S | 0.0% | 09/01 | 09/01 | |
| ORKA | Sandler Laura Lee | COO | sale10b5-1 | 1.00k | -$9.10M | S | 0.0% | 09/01 | 09/01 | |
| ORKA | Sandler Laura Lee | COO | exercise10b5-1 | 5.00k | $3.90M | M | 0.0% | 09/01 | 09/01 | |
| ORKA | Klein Lawrence Otto | CEO | exercise10b5-1 | 75.0k | $0 | M | 0.0% | 09/01 | 09/01 | |
| ORKA | Klein Lawrence Otto | CEO | sale10b5-1 | 4.80k | -$44.3M | S | 0.0% | 09/01 | 09/01 | |
| ORKA | Klein Lawrence Otto | CEO | sale10b5-1 | 63.5k | -$584M | S | 0.0% | 09/01 | 09/01 | |
| ORKA | Klein Lawrence Otto | CEO | sale10b5-1 | 6.60k | -$59.9M | S | 0.0% | 09/01 | 09/01 | |
| ORKA | Klein Lawrence Otto | CEO | exercise10b5-1 | 75.0k | $58.5M | M | 0.0% | 09/01 | 09/01 | |
| ORKA | Goncalves Joana | CMO | exercise10b5-1 | 3.50k | $0 | M | −18.2% | 08/17 | 08/17 | |
| ORKA | Goncalves Joana | CMO | exercise10b5-1 | 3.50k | $0 | M | −18.2% | 08/17 | 08/17 | |
| ORKA | Goncalves Joana | CMO | sale10b5-1 | 2.48k | -$27.9M | S | −18.2% | 08/17 | 08/17 | |
| ORKA | Goncalves Joana | CMO | sale10b5-1 | 3.32k | -$37.1M | S | −18.2% | 08/17 | 08/17 | |
| ORKA | Goncalves Joana | CMO | sale10b5-1 | 300 | -$3.31M | S | −18.2% | 08/17 | 08/17 | |
| ORKA | Goncalves Joana | CMO | sale10b5-1 | 900 | -$9.86M | S | −18.2% | 08/17 | 08/17 | |
| ORKA | Goncalves Joana | CMO | exercise10b5-1 | 3.50k | $2.73M | M | −18.2% | 08/17 | 08/17 | |
| ORKA | Goncalves Joana | CMO | exercise10b5-1 | 3.50k | $2.39M | M | −18.2% | 08/17 | 08/17 |
Oruka Therapeutics, Inc. Insider Activity FAQ
SEC Form 4 contextWho recently reported transactions at Oruka Therapeutics, Inc.?
Sandler Laura Lee, Klein Lawrence Otto, Goncalves Joana.
When was the latest reported open-market purchase?
No code-P purchase is available for this period.
When was the latest reported open-market sale?
Sandler Laura Lee reported a sale on Sep 01, 2026 valued at $36.8M. Read the SEC filing.
What is the recent purchase and sale balance?
Net open-market selling in the selected period was $8,129,467.75. Sales can occur for many non-investment reasons.
Where can I see the original SEC filing?
Every transaction row and latest-activity fact links to its original SEC filing.
What do these Form 4 transaction codes mean?
P and S generally describe open-market or private purchases and sales. A, D, F, M, X, G, J, and V describe awards, issuer dispositions, tax withholding, exercises, gifts, other transactions, and voluntary early reports; review each filing and its footnotes for context.